Abbott manufactures and markets medical devices, blood glucose monitoring kits, nutritional healthcare products, diagnostic products and equipment, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, and molecular and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
| Website: | www.abbottinvestor.com |
| Main Phone: | +1 224 667-6100 |
| Address: | 100 Abbott Park Road |
| State: | IL |
| City / Town: | Abbott Park |
| Country: | USA |
| Postal Code: | 60064-6400 |
| Exchange: | NYE |
| CEO: | Miles D. White |
| Employees: | 103000 |
| NAICS: | Surgical and Medical Instrument Manufacturing(339112) |
The last six times the Fed cut interest rates during an economic expansion, the S&P 500 gained almost 10% on average over the following three months. Healthcare stocks did even better
Investors that don’t insist on a fiduciary level of service could find themselves pushed into flawed investments based on incomplete and conflicted research.
The highest-selling prescription drug in the world is AbbVie's Humira.
At the size of a dime, it's the first pediatric mechanical heart valve developed to treat newborns and infants.
Health care’s massive size offers opportunities for investors.
One of the company’s key strengths is its experienced leadership team.
Combining an advanced medical device with the latest in mobile technology (Image: Pharmaphorum).
AbbVie is on track to launch more than 20 new products through 2020.
Eliminates the need for routine fingertip pricking.
AGTC is developing treatments for severe opthalmological diseases using gene therapy.
Gathering Data... Please wait Abbott manufactures and markets medical devices, blood glucose monitoring kits, nutritional healthcare products, diagnostic products and equipment, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, and molecular and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
| Website: | www.abbottinvestor.com |
| Main Phone: | +1 224 667-6100 |
| Address: | 100 Abbott Park Road |
| State: | IL |
| City / Town: | Abbott Park |
| Country: | USA |
| Postal Code: | 60064-6400 |
| Exchange: | NYE |
| CEO: | Miles D. White |
| Employees: | 103000 |
| NAICS: | Surgical and Medical Instrument Manufacturing(339112) |
The last six times the Fed cut interest rates during an economic expansion, the S&P 500 gained almost 10% on average over the following three months. Healthcare stocks did even better
Investors that don’t insist on a fiduciary level of service could find themselves pushed into flawed investments based on incomplete and conflicted research.
The highest-selling prescription drug in the world is AbbVie's Humira.
At the size of a dime, it's the first pediatric mechanical heart valve developed to treat newborns and infants.
Health care’s massive size offers opportunities for investors.
One of the company’s key strengths is its experienced leadership team.
Combining an advanced medical device with the latest in mobile technology (Image: Pharmaphorum).
AbbVie is on track to launch more than 20 new products through 2020.
Eliminates the need for routine fingertip pricking.
AGTC is developing treatments for severe opthalmological diseases using gene therapy.
| Last Price 82.79 | Change $ 0.41 | Change % 0.50 | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask N/A | Ask Size 0.00 |
| Open 82.41 | High 83.32 | Low 82.03 | Prev Close 82.38 |
| Last Trade | Volume 5.2 mi | 52 Wk Hi 88.76 | 52 Wk Low 65.44 |
| Market Cap 146.3 bi | Ex-Div Date | Div Rate 1.28 | Yield 1.5460 |
| Shares 1,767,397,615.00 | EPS (TTM) 1.63 | PE Ratio 48.80 | Exchange NYSE |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 32 | 614 |
| Number of Buys | 16 | 135 |
| Number of Sells | 16 | 479 |
| Net Activity | 9943 | 787821 |
| Last 10 Buys | Shares |
|---|---|
| Daniel J. Starks | 1,000 |
| Daniel J. Starks | 1,000 |
| Daniel J. Starks | 1,000 |
| Daniel J. Starks | 1,000 |
| Daniel J. Starks | 1,000 |
| Daniel J. Starks | 1,000 |
| Daniel J. Starks | 1,000 |
| Daniel J. Starks | 1,000 |
| Daniel J. Starks | 1,000 |
| Daniel J. Starks | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Daniel Gesua Sive Salvadori | 1,000 |
| Daniel Gesua Sive Salvadori | 1,000 |
| Sharon J. Bracken | 1,000 |
| Sharon J. Bracken | 1,000 |
| Sharon J. Bracken | 1,000 |
| Sharon J. Bracken | 1,000 |
| Jaime Contreras | 1,000 |
| Roger Bird | 1,000 |
| Roger Bird | 1,000 |
| Roger Bird | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 71 | 71 | 71 | 71 |
| Low Target Price Estimate | 56 | 56 | 56 | 56 |
| Mean Target Price Estimate | 67.12 | 67.12 | 67.12 | 67.12 |
| Standard Deviation | 4.66 | 4.66 | 4.66 | 4.66 |
| Date of Most Recent Estimate | 05/22/18 | 05/22/18 | 05/22/18 | 05/22/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-06-15 |
| 8-K | Report of unscheduled material events or corporate changes. | 31 | 2018-06-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| SD | Specialized Disclosure Report | 17 | 2018-05-31 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-16 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 16 | 16 | 16 | 16 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.35 | 1.35 | 1.35 | 1.35 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
